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explained by improved survival after cancer diagnosis. Several studies have shown improved survival after diagnosis of KS (7) (8) (9) and NHL (7, (9) (10) (11) (12) (13) (14) (15) since the advent of cART. The few studies that have examined trends in cancer survival have given conflicting results for HL (16, 17) and anal cancer (15, 17, 18) , and no improvement for lung cancer (15, 17) . Most of these studies compared survival between the pre-cART and early cART periods (10) (11) (12) (13) (14) (15) (16) . Recently, a study comparing cancer patients with AIDS with HIV-seronegative cancer patients showed that survival after cancer diagnosis had improved in the cART era, reducing the survival gap between the 2 populations from 5-fold (HR = 5.1; 95% CI [4.3-6.1]) in the pre-cART period to 3-fold (HR = 2.9; 95% CI [2.6-3.3] ) in the cART period (19) . However, results for AIDS patients cannot be generalized to all HIV-infected patients, as patients with AIDS in the precART era differ from their counterparts in the cART era. Indeed, in the pre-cART era most individuals with HIV infection progressed to AIDS, while this is now mainly the case of only late-diagnosed patients.
It is therefore important to examine temporal trends in survival after cancer diagnosis in all HIV-infected individuals. 6 As survival trends for ADCs and NADCs have rarely been studied, and as no data are available for individual NADCs, we examined time trends in survival after diagnosis for each of the six most frequent cancers, using data from the French Hospital Database on HIV (FHDH ANRS-CO4) collected from 1992 through 2009. We then compared survival among HIV-infected individuals to age-and sex-standardized survival in individuals with cancer in the general population in France in 2001-2004. 7 
MATERIAL AND METHODS
The FHDH (20) is an ongoing, open, prospective cohort created in 1989, with participation by 70 general and university hospitals in France. The only inclusion criteria are HIV type 1 (HIV-1) or type 2 (HIV-2) infection and written informed consent. Among HIV-1 infected patients aged between 15 and 84 years at FHDH enrollment and followed-up between 1992 and 2009, we selected individuals diagnosed with cancer during this period. Patients who had no available CD4 cell count during the 12 months prior to cancer diagnosis were excluded. If several CD4 cell counts were available during this period, the last one was used in the analysis.
We examined the most frequent cancers diagnosed among HIV-infected individuals, namely KS, NHL, HL, and lung, liver, and anal cancer. As the prognosis of KS is worse for visceral forms, we separately analyzed visceral (mostly lung, gastrointestinal, or multiple organs) and non-visceral KS (skin, skin structures, palate and lymph nodes). The International Classification of Diseases, Ninth Revision (ICD-9) was used to code cancers in FHDH before 1997 and the Tenth Revision (ICD-10) thereafter (Supplementary table 1 Death from all causes was the analyzed event, while patients alive at the last visit to an FHDH center or 5 years after cancer diagnosis (whichever occurred earlier) were censored. The Kaplan-Meier method was used to estimate 5-year survival after cancer diagnosis during the four periods, and the log-rank test was used to analyze differences in survival. Multivariate Cox proportional hazard models were used to evaluate the calendar-period effect on the risk of death, using the period 1997-2000 as reference. First, we adjusted Cox models for sex and age at diagnosis. Second, to determine whether changes in survival were influenced by changes in patient characteristics over time, we also included the following characteristics known to impact survival among HIV-infected individuals and which might have changed over time: sex, age at cancer diagnosis, geographic origin, HIV transmission group, region of care, hepatitis C virus together with the national identity number. When vital status was not known by these two queries, other sources were used as medical records, the municipality of residence or health insurance.
Because the age and sex distributions differ between the HIV-infected and general populations (1), 5-year survival in the general population was standardized for each cancer by using the direct method, based on the age and sex structure of HIV-infected patients diagnosed with the same cancer. Moreover for NHL, because histologic subtypes of NHL in HIV patients are mostly B subtypes (24) , with about 44% of HIV- Table 2 according to the period of cancer diagnosis in the period 1992-2009, and in Table 3 for the period 1997-2009.
RESULTS
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AIDS-defining cancers
Between the pre-cART and late cART periods, 5-year survival rates rose from 14% to 83% after visceral KS, from 36% to 92% after non visceral KS, and from 15% to 65% after NHL ( Figure 1 ). As shown in Table 2 , in analyses adjusted for age and sex, the 5-year cancer mortality declined significantly between the pre-cART and early cART periods; similar decline was observed after adjustment for all the other potential confounders, with a HR in 1992-1996 compared to 1997-2000 of 2.34 for visceral KS, 3.19 for non-visceral KS and 1.38 for NHL. The 5-year cancer mortality, adjusted for age and sex, also declined significantly during the cART era for KS whether visceral or non-visceral and for NHL (Table 3) . After adjustment for all confounders, the 5-year adjusted HR of death was reduced by around 2-fold in the latecART period compared to the early-cART period, and the reduction was significant for NHL (Ptrend <0.0001) and non-visceral KS (Ptrend=0.0269) and was not significant for visceral KS (Ptrend=0.3233).
Non AIDS-defining cancers
As shown in Figure 2 , between the pre-cART and late cART periods, 5-year survival increased significantly from 48% to 87% after HL and from 17% to 19% after liver cancer. For lung and anal cancers, the difference in the 5-year survival distributions was not statistically significant across the calendar periods, with an overall 5-year survival rate of 16% after lung cancer and 65% after anal cancer during the entire study period.
In analyses adjusted for age and sex, the 5-year HR of death after HL diagnosis was 1.62 (95% CI [1.04-2.53]) in the pre-cART period compared to the early cART period (Table 2) , but an improvement in survival was observed during the cART era even after adjustment for all confounders including viral load at HL diagnosis (Ptrend =0.0071) ( Table 3) . For lung cancer, the adjusted 5-year HR of death remained stable across the calendar periods. In analyses adjusted for age and sex, the 5-year HR of death after liver cancer did not change significantly between the pre-cART and early cART periods (Table 2) . During the cART era, survival after liver cancer diagnosis improved after adjustment for potential confounders (Ptrend =0.0198), but was no longer significantly improved after adjustment for viral load (Ptrend =0.2237) ( Table   3 ). In the fully adjusted model, the 5-year HR of death after anal cancer diagnosis was 3.22 (95% CI [1.02-
10
.09]) in the pre-cART period compared to the early cART period (Table 2) , but there was no significant change during the cART era (Ptrend =0.7239) ( Table 3) .
Comparison with the general population
For cases diagnosed in 2001-2004, Table 4 shows 5-year crude survival rates for the general population in the first column, 5-year standardized survival rates for the general population in the second column and 5-year survival rates for the HIV-infected population in the third column, with respect to NHL, lung cancer, HL, liver cancer and anal cancer. For NHL, the standardized 5-year survival rate in the general population was estimated at 74% for all subtypes, being 70% for DLBCL subtype ( Table 4 ). The age-and sex-standardized survival rate was higher in the general population than among HIV-infected individuals with respect to NHL (either for all subtypes or DLCBL subtype) and HL. Regarding solid tumors, 5-year survival rates among HIV-infected individuals were close to age-and sex-standardized rates in the general population. Another limitation of the study is not taking into account of the causes of death in the analyses, although, in patients with multiple co-morbidities, the collected causes of death could often be incorrect, incomplete or impossible to dismantle. For instance, for HIV-infected persons who have cancer, the collected cause of death could be the HIV infection, the cancer itself, the complications of the cancer treatment, or other causes. It is therefore difficult to rely on these data to ascertain the cause of death, and to determine whether differences, if any, in overall mortality between the HIV-infected and general populations are due to cancer-specific or HIV-specific mortality or both. However, the adjusted models (Table 3) give an insight of whether the improvements in survival over time, if any, are related to better cancer treatment or better treatment of HIV. Indeed, as CD4 cell count and HIV viral load depend strongly on HIV treatment adjusting for CD4 cell count and HIV viral load account for the evolution of the HIV-specific mortality that depends on the improvement in HIV treatment. Therefore, we think that the remaining effect on the evolution of survival after adjusting for CD4 cell count and HIV viral load is more likely explained by the change over time in the cancer treatment in the HIV-infected persons.
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DISCUSSION
The improvement in survival after KS diagnosis is consistent with that seen in other studies comparing the pre-cART era with the cART era (7-9). Interestingly, we found that survival improved after diagnosis of both visceral and non-visceral KS. The continued improvement in survival during the cART period 15 among patients diagnosed with visceral KS was likely explained by the increasing proportion of HIVinfected individuals receiving antiretroviral therapy (25) .
As observed in other studies, survival after NHL diagnosis improved between the pre-cART and early cART periods (9) (10) (11) (12) (13) (14) (15) , and continued to improve during the cART era (until 2009). Between the pre-and early-cART periods, the improvement in survival after HL was nearly significant and survival improved during the cART era. This improvement in survival is similar to that reported by a single institution in Our results for anal cancer confirm those of a previous study that showed a significant improvement between the pre-cART and early cART periods (15): the 5-year HR of death in our study was 3 times higher among individuals diagnosed with anal cancer in 1992-1996 than in those diagnosed with this cancer in 1997-2000. Another study showed no such change, probably owing to the small number of cases (n=26) (18) . Nevertheless, we found that survival was stable during the cART era, being similar to that of 
